Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Crona D, Innocenti F.

Biomark Med. 2012 Jun;6(3):349-62. doi: 10.2217/bmm.12.19. Review.

2.

Cancer pharmacogenomics: early promise, but concerted effort needed.

McLeod HL.

Science. 2013 Mar 29;339(6127):1563-6. doi: 10.1126/science.1234139. Review.

3.

Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.

Cortejoso L, López-Fernández LA.

Pharmacogenomics. 2012 Jul;13(10):1173-91. doi: 10.2217/pgs.12.95.

PMID:
22909207
4.

Germline genetic testing to predict drug response and toxicity in oncology--reality or fiction?

Soh TI, Yong WP.

Ann Acad Med Singapore. 2011 Aug;40(8):350-5. Review.

5.

Somatic pharmacogenomics in cancer.

Ikediobi ON.

Pharmacogenomics J. 2008 Oct;8(5):305-14. doi: 10.1038/tpj.2008.8. Epub 2008 Aug 5. Review.

PMID:
18679398
6.

Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.

Hutson JR, Weitzman S, Schechter T, Arceci RJ, Kim RB, Finkelstein Y.

Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):709-22. doi: 10.1517/17425255.2012.680884. Epub 2012 Apr 18. Review.

PMID:
22509821
7.

Pharmacogenetics of cancer drugs.

Hertz DL, Rae J.

Annu Rev Med. 2015;66:65-81. doi: 10.1146/annurev-med-053013-053944. Epub 2014 Oct 29. Review.

PMID:
25386932
8.

Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

Walko CM, McLeod H.

Nat Clin Pract Oncol. 2009 Mar;6(3):153-62. doi: 10.1038/ncponc1303. Epub 2009 Jan 27. Review.

PMID:
19174777
9.

The role of pharmacogenetics in cancer therapeutics.

Yong WP, Innocenti F, Ratain MJ.

Br J Clin Pharmacol. 2006 Jul;62(1):35-46. Review.

10.

Cancer pharmacogenomics: strategies and challenges.

Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ.

Nat Rev Genet. 2013 Jan;14(1):23-34. doi: 10.1038/nrg3352. Epub 2012 Nov 27. Review.

11.

Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.

Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ.

Curr Top Med Chem. 2012;12(15):1649-59. Review.

PMID:
22978339
12.

Clinically relevant cancer biomarkers and pharmacogenetic assays.

Patel JN, Mandock K, McLeod HL.

J Oncol Pharm Pract. 2014 Feb;20(1):65-72. doi: 10.1177/1078155212473862. Epub 2013 Jan 24. Review.

PMID:
23353710
13.

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.

Hertz DL, McLeod HL.

J Hum Genet. 2013 Jun;58(6):346-52. doi: 10.1038/jhg.2013.42. Epub 2013 May 16. Review.

PMID:
23677053
14.

Expression biomarkers for clinical efficacy and outcome prediction in cancer.

Strand KJ, Khalak H, Strovel JW, Ebner R, Augustus M.

Pharmacogenomics. 2006 Jan;7(1):105-15. Review.

PMID:
16354128
15.

Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy.

Mladosievicova B, Carter A, Kristova V.

Neoplasma. 2007;54(3):181-8. Review.

PMID:
17447847
16.

[Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].

Lehne G, Bjørheim J, Saeter G.

Tidsskr Nor Laegeforen. 2007 Apr 19;127(8):1040-4. Review. Norwegian.

17.

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.

O'Donnell PH, Ratain MJ.

Mol Oncol. 2012 Apr;6(2):251-9. doi: 10.1016/j.molonc.2012.01.005. Epub 2012 Jan 21. Review.

18.

Using germline genotype in cancer pharmacogenetic studies.

McWhinney SR, McLeod HL.

Pharmacogenomics. 2009 Mar;10(3):489-93. Review.

19.

Germline genetic variation, cancer outcome, and pharmacogenetics.

Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G.

J Clin Oncol. 2010 Sep 10;28(26):4029-37. doi: 10.1200/JCO.2009.27.2336. Epub 2010 Aug 2. Review.

PMID:
20679599
20.

Application of genotype-guided cancer therapy in solid tumors.

Patel JN.

Pharmacogenomics. 2014 Jan;15(1):79-93. doi: 10.2217/pgs.13.227. Review.

PMID:
24329193
Items per page

Supplemental Content

Write to the Help Desk